Covered recipient · General Payments record
NATAN BAR-CHAMA
Allopathic & Osteopathic Physicians Urology
General Payments · PY2018–2024
$61,211.64
- Reported across 57 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $24,907.50 | 3 |
| Travel and Lodging | $10,106.06 | 3 |
| Food and Beverage | $1,155.51 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| F. Hoffmann-La Roche AG | $21,251.15 | 6 |
| Genentech, Inc. | $14,333.68 | 3 |
| Genentech USA, Inc. | $143.61 | 1 |
| Antares Pharma, Inc. | $125.00 | 1 |
| Endo USA, Inc. | $125.00 | 1 |
| Amgen Inc. | $124.98 | 1 |
| ABBVIE INC. | $65.65 | 3 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.18 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103276863 | CMS |
| ABBVIE INC. | $15.85 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103276865 | CMS |
| ABBVIE INC. | $32.62 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103276867 | CMS |
| Amgen Inc. | $124.98 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115439957 | CMS |
| Antares Pharma, Inc. | $125.00 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146448591 | CMS |
| Endo USA, Inc. | $125.00 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138577254 | CMS |
| F. Hoffmann-La Roche AG | $671.97 | 06/14/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1133078564 | CMS |
| F. Hoffmann-La Roche AG | $337.59 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133078568 | CMS |
| F. Hoffmann-La Roche AG | $9,371.72 | 06/14/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1133078572 | CMS |
| F. Hoffmann-La Roche AG | $62.37 | 06/14/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1133078576 | CMS |
| F. Hoffmann-La Roche AG | $5,520.00 | 06/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1133078580 | CMS |
| F. Hoffmann-La Roche AG | $5,287.50 | 11/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1133078584 | CMS |
| Genentech USA, Inc. | $143.61 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133078548 | CMS |
| Genentech, Inc. | $92.34 | 03/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133078560 | CMS |
| Genentech, Inc. | $141.34 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133078552 | CMS |
| Genentech, Inc. | $14,100.00 | 05/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1133078556 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.